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The insulin-like growth factor 1 gene (IGF1) is a strong candidate gene for a breast cancer susceptibility model. We investigated a
dinucleotide repeat 969bp upstream from the transcription start site of the IGF1 gene for possible associations with plasma IGF1
levels and breast cancer risk in a multiethnic group of postmenopausal women. Furthermore, we investigated the relation between
race/ethnicity, mean plasma IGF1 levels and breast cancer rates in the Hawaii/Los Angeles Multiethnic Cohort. The mean age-
adjusted IGF1 level among Latino-American women, 116ngml
 1, was statistically significantly lower than the mean age-adjusted IGF1
levels for each of the three other racial/ethnic groups, African-American, Japanese-American and Non-Latino White women (146,
144 and 145ngml
 1, respectively) (Po0.0001). Latino-American women have the lowest breast cancer rates of any racial/ethnic
group in the cohort. These results support the investigation of an expansion of the hypothesis for an important role of IGF1 in breast
cancer tumorigenesis to different racial/ethnic groups and to postmenopausal women. It is unlikely that any involvement of IGF1 in
breast cancer aetiology is mediated by the IGF1 dinucleotide repeat polymorphism, which was not significantly associated with
circulating IGF1 levels nor breast cancer risk in this study. Research into relevant determinants of IGF1 levels in the blood must
continue.
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The insulin-like growth factor 1 (IGF1) protein has been
implicated in breast cancer because of its mitogenic and
antiapoptotic effect on mammary epithelial cells (Furlanetto and
DiCarlo, 1984; Westley and May, 1994; Kleinberg, 1998). Epide-
miological work epitomised by a paper from Hankinson et al
(1998) has shown an increased risk for breast cancer in
premenopausal women with high prediagnostic plasma IGF1.
Byrne et al (2000) subsequently showed that mammographic
density, one of the strongest breast cancer risk factors, was
positively correlated with plasma IGF1 in premenopausal but not
postmenopausal control women. Although these initial findings
were limited to premenopausal women, postmenopausal IGF1
levels may also be an important determinant of breast cancer risk
if considered as a component of lifetime or intratissue exposure.
Assessment of lifetime or intratissue exposure may be improved by
the availability of genetic determinants. An early report suggested
that the homozygous status for a (CA)19 microsatellite variant
969bp upstream from the transcription start site in the IGF1 gene
(IGF1) was predictive of low serum IGF1 in Caucasian men and
postmenopausal women. We hypothesised that the (CA)19 homo-
zygous genotype (19/19) might indicate women with a decreased
lifetime exposure to IGF1 and consequently, a decreased suscept-
ibility to breast cancer. We examined the role of IGF1 in
postmenopausal breast cancer among women from four major
racial/ethnic groups (African American, Japanese American,
Latino American, White) in the Hawaii and Los Angeles Multi-
ethnic Cohort. We first examined whether the mean plasma IGF1
levels were correlated with patterns of breast cancer risk by the
racial/ethnic group. We then attempted to confirm whether a
microsatellite variant for IGF1 was predictive of plasma IGF1 levels
in different racial/ethnic groups and to test whether the variant
was a marker of breast cancer risk in our postmenopausal
multiethnic population.
MATERIALS AND METHODS
Study subjects
Participants included in these analyses were selected from a large
multiethnic cohort (MEC) study in Hawaii and Los Angeles
initiated with emphasis on diet and lifestyle characteristics in the
aetiology of cancer. The cohort was established between 1993 and
1996 from driver’s licence files in Hawaii and Los Angeles,
including 215251 men and women, ages 45–75 years at the time of
enrollment. The MEC includes primarily African Americans,
Japanese Americans, Native Hawaiians, Latino-Americans and
Non-Latino Whites. Baseline data were collected on all cohort
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smembers via a mailed questionnaire that contained five sections:
(a) background, including medical history and family cancer
history; (b) diet history; (c) medication use; (d) physical activity
and (e) female reproductive history, including the use of
hormones. Details of the study have been published previously
(Kolonel et al, 2000). For setting up nested case–control studies,
breast cancer cases and potential controls were recontacted by
letter and phone call, followed by a home visit to collect a blood
specimen. Blood draw was completed in the morning, typically at
the person0s home, after informed consent was obtained.
Participation rates for providing a blood sample on request were
74% for cancer cases and 66% for cohort controls. Case
ascertainment was completed through the Surveillance, Epide-
miology and End Results (SEER) cancer registries in Hawaii and
Los Angeles.
We tested the association between circulating plasma IGF1 levels
and racial/ethnic group in 406 healthy, postmenopausal women.
For a subset of these women (230 randomly selected from the four
racial/ethnic strata), genotyping of the IGF1 (CA)n microsatellite
variant also was completed for the assessment of phenotype/
genotype correlation. We selected postmenopausal women with no
history of cancer, who had not taken hormone therapy within 2
weeks of blood draw. A subject was defined as postmenopausal, if
she met any one of three criteria: (1) over age 55 and periods
stopped; (2) 55 years or younger, periods stopped and no
hysterectomy; (3) 55 years old or younger, periods stopped and
bilateral oophorectomy. At the time the sample was selected
(January, 2000), plasma was available for IGF1 testing among 123
African-American, 71 Japanese-American, 154 Latino-American
and 58 Non-Latino White postmenopausal women.
A total of 800 postmenopausal women (400 cases and 400
controls) from the same four racial/ethnic groups were selected for
a nested case–control study of the microsatellite (CA)19 variant
and breast cancer risk. Women included in the case–control
analysis were selected irrespective of hormone therapy status. Of
the 800 women, 56 (29 cases and 27 controls) reported having a
prevalent breast and/or uterine cancer on their questionnaire and
were subsequently excluded from the analysis. Three women were
missing weight or height values. The remaining 368 cases and 373
controls were successfully genotyped. A subset (134/373; 36%) of
the controls selected for this case–control data set overlapped with
controls selected for the plasma IGF1 by racial/ethnic group
analysis described above.
IGF1 plasma levels
Plasma IGF1 was quantified in the Reproductive Endocrine
Research Laboratory at USC, under the supervision of Dr Frank
Stanczyk. IGF1 was measured by direct radioimmunoassay (RIA)
using commercial kits obtained from Quest Diagnostics at the
Nichols Institute (San Juan Capistrano, CA, USA). All samples
were analysed in a single batch, meaning that kits with identical lot
numbers were used and all assays were performed by the same
individual. The intra-assay coefficients of variation for the RIA
assay ranged from 9.5 to 13.8% (Carmina et al, 1995, 1999).
IGF1 (CA)n genotyping
Genotyping of the microsatellite (CA)n variant was performed using
PAGE gel electrophoresis. We performed PCR amplification of the
DNA region surrounding the microsatellite repeat in question using
identical primers to those used in the study by Rosen et al (1998).
Their sequences were as follows 50GCTAGCCAGCTGGTGGTGTTATT30
and 30ACCACTCTGGGAGAAGGGTA50. All PCR was performed
using a PTC-100 Thermocycler (MJ Research, Waltham, MA,
USA). We extracted DNA from the buffy coats of peripheral blood
samples using the Puregene genomic DNA isolation kit (Gentra
Systems, Minneapolis, MN, USA). We used a modified genotyping
protocol as described by Rosen et al (1998). A total of 20ng of
DNA template, 1.25pmols of each primer, 0.25mM of each
deoxynucleotide triphosphate, 2.5mM MgCl2, 2% dimethyl sulph-
oxide, 1.5U Taq polymerase (Promega, Madison, WI, USA) and
the manufacturer’s recommended buffers were combined in 25ml
reactions. The forward primer was labelled with
33P using T4
polynucleotide kinase (Amersham-Pharmacia, Piscataway, NJ,
USA). A ‘touchdown’ PCR cycling protocol was used which
consisted of 35 cycles in total. The programme started with a 45s
denaturation at a temperature of 941C. The first cycle continued
with a 30s annealing phase at 641C and finished with a 30s 721C
extension. The annealing temperature was decreased by 11Ci n
each of the next nine cycles, and then was maintained at 551C for
25 cycles. Denaturation at 941C for 45s, and extension at 721C for
30s were consistent throughout the entire programme. The final
extension was held for 5min at 721C. The radiolabelled, denatured
PCR product was screened on a polyacrylamide gel by electro-
phoresis. Autoradiographs were exposed for 12–18h. Two
investigators scored all genotypes independently and random
samples were rerun periodically to check consistency across the
entire sample. The same (CA)19 homozygote control and a (CA)21
homozygote control were run on each genotyping gel. The
noninformative samples were repeated in subsequent gels thereby
reducing our noninformative rate to less than 1% among cases and
controls.
In order to orient the genotype information attained from the
PAGE gel electrophoresis assay in terms of the number of
dinucleotide repeats, we sequenced a number of homozygous
samples using an ABI 3700 automatic sequencer (ABI, Foster City,
CA, USA). Two independent investigators read the sequencing
output and were able to identify which sample contained the
(CA)19 homozygote, thus allowing us to orient the other genotypes
in relation to the (CA)19 on the PAGE gels.
Data analysis
Analysis of variance (ANOVA) was used to test differences in
crude and age-adjusted mean IGF1 by racial/ethnic group and
IGF1 genotype. We used a modified categorisation scheme for the
IGF1 (CA)n genotype based on the paper by Rosen et al (1998)
(non-19/non-19, non-19/19 and 19/19), given their prior finding of
an association between the (CA)19 genotype and IGF1 concentra-
tion in the blood. Means presented are least-squares means. The
square root transformed plasma IGF1 levels produced the best
approximate normal distribution, but the results of an analysis of
the data using square-root transformations did not differ from
results using data that had not been transformed. We therefore
present the straightforward means derived from the nontrans-
formed plasma IGF1 values. Odds ratios for association between
the genotype and breast cancer risk were calculated using
unconditional logistic regression. Odds ratios were calculated for
the IGF1 genotype categorised by the number of 19 alleles (CA19)
as described above. Estimates were adjusted for age and racial/
ethnic group when not stratified by race. Women were categorised
into four levels of age (o64, 65–68, 69–72, 73+).
All analyses were performed in SAS v8 (SAS Insitute, Cary, NC,
USA).
RESULTS
Mean IGF1 plasma concentrations by racial/ethnic group
Table 1 shows characteristics and mean plasma IGF1 levels for the
406 healthy postmenopausal women selected for this analysis by
racial/ethnic group. In our sample, African-American women had
the oldest mean age at blood draw (70.2 years), while Latino-
American women had the youngest mean age (64.9 years). Body
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across racial/ethnic groups in our sample. African-American and
Latino-American women had higher mean body mass index (BMI)
scores (28.5 and 28.7, respectively) than White (26.1) or Japanese-
American women (23.9). Latino-Americans had significantly lower
mean plasma IGF-1 levels (118ngml
 1 (crude) and 116ngml
 1
(age-adjusted)). African-American, Japanese-American and Non-
Latino White women had plasma IGF1 levels that did not differ
significantly from each other, with age-adjusted means of 146, 144
and 145ngml
 1, respectively. Further adjustment for BMI in the
model did not change these results.
IGF1 (CA)n genotype and mean IGF1 plasma
concentrations by racial/ethnic group
IGF1 (CA)n genotype results for a sample (N¼230) of the 406
control women described above are shown in Table 2. In Non-
Latino White and Latino-American women, the (CA)19 homo-
zygote (19/19) is the most common genotype (44.7 and 42.7%,
respectively), but for African-American women, the 19/18
genotype is most common (20.0%) and in Japanese-Americans,
21/19 is the most common genotype (24.0%). w
2 test for differences
in the distribution of genotypes across racial ethnic groups are
significant for the three-level categorisation strategy presented
here (19/19, 19/non-19, non-19/non-19) and for the categorisation
used by Rosen et al (1998) (19/19 vs non-19). There is no evidence
for departure from Hardy–Weinberg equilibrium in any of the
racial/ethnic groups. In addition, we found no consistent
statistically significant association between age and genotype
among controls, cases or all women combined, providing no
evidence for confounding by age.
In accordance with the findings previously described on the
association between serum IGF1 levels and the (CA)19 genotype
(Rosen et al, 1998), we compared mean plasma IGF1 concentration
across three (CA)n microsatellite genotype categories (non-19/
non-19, non-19/19 and 19/19) (Table 3). We found that the
Table 1 Characteristics and mean plasma IGF1 level (ngml
 1) by racial/ethnic group
Variable African American Japanese American Non-Latino White Latino American P
a
No. of subjects (%) 123 (30) 71 (18) 58 (14) 154 (38)
Mean age (years) 70.2 68.2 67.9 64.9 o0.0001
Mean height (in) 64.1 60.2 64.0 62.4 o0.0001
Mean weight (lb) 166.5 122.6 151.7 158.8 o0.0001
Mean BMI (kgm
 2) 28.5 23.9 26.1 28.7 o0.0001
Mean plasma IGF1 (ng ml
 1)
b
Crude 145 (135, 154) 145 (132, 158) 145 (130, 159) 118 (109, 127) o0.0001
Age adjusted
c 146 (136, 156) 144 (131, 157) 145 (130, 159) 116 (107, 125) o0.0001
aP-value derived from ANOVA and analysis of covariance models.
bThe associated 95% confidence limits are given in parentheses..
cAdjusted for age as a categorical variable.
Table 2 IGF1 (CA)n microsatellite genotype frequencies among healthy postmenopausal women tested for plasma IGF1 level by racial/ethnic group
African American Japanese American Non-Latino White Latino American
Genotype
a N (%) N (%) N (%) N (%)
23/17 0 (0) 1 (2) 0 (0) 0 (0)
22/19 1 (1.5) 0 (0) 3 (6.4) 1 (1.5)
21/21 2 (3.0) 2 (4.0) 0 (0) 2 (2.9)
21/20 1 (1.5) 4 (8.0) 1 (2.1) 3 (4.4)
21/19 8 (12.3) 12 (24.0) 5 (10.6) 11 (16.2)
21/18 3 (4.6) 5 (10.0) 0 (0) 2 (2.9)
21/17 1 (1.5) 2 (4.0) 1 (2.1) 0 (0)
21/16 1 (1.5) 0 (0) 0 (0) 0 (0)
20/20 3 (4.6) 0 (0) 1 (2.1) 2 (2.9)
20/19 7 (10.8) 8 (16.0) 12 (25.5) 14 (20.6)
20/18 2 (3.1) 0 (0) 0 (0) 1 (1.5)
20/16 1 (1.5) 0 (0) 0 (0) 0 (0)
19/19 10 (15.4) 5 (10.0) 21 (44.7) 29 (42.7)
19/18 13 (20.0) 3 (6.0) 3 (6.4) 2 (2.9)
19/17 1 (1.5) 6 (12.0) 0 (0) 1 (1.5)
19/16 3 (4.6) 0 (0) 0 (0) 0 (0)
18/18 4 (6.2) 2 (4.0) 0 (0) 0 (0)
18/17 3 (4.6) 0 (0) 0 (0) 0 (0)
18/16 1 (1.5) 0 (0) 0 (0) 0 (0)
Non-19/non-19 22 (33.9) 16 (32.0) 3 (6.4) 10 (14.7)
Non-19/19 33 (50.8) 29 (58.0) 23 (48.9) 29 (42.7)
19/19 10 (15.4) 5 (10.0) 21 (44.7) 29 (42.7)
aNumber of (CA) repeats for the two alleles.
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homozygote genotype and the lowest mean plasma IGF1 level
among the four racial/ethnic groups. Among Latino-American
women there was an inverse relation between the number of 19
alleles and mean plasma IGF1 in the crude and age-adjusted
analyses. However, this pattern was not evident in any other ethnic
group. Furthermore, none of the differences in mean plasma IGF1
level across genotype were statistically significant.
Table 3 Mean plasma IGF1 level (ngml
 1) by (CA)n microsatellite genotype and racial/ethnic group
a
Genotype African American Japanese-American Non-Latino White Latino American
Crude
Non-19/non-19 150 (121, 180) 144 (119, 169) 160 (104, 216) 149 (107, 192)
Non-19/19 166 (142, 190) 148 (130, 167) 142 (121, 162) 126 (101, 151)
19/19 150 (106, 194) 146 (101, 190) 146 (125, 167) 118 (93, 142)
Adjusted
b
Non-19/non-19 149 (118, 179) 144 (120, 168) 157 (97, 217) 148 (103, 193)
Non-19/19 168 (142, 194) 147 (129, 165) 141 (121, 162) 126 (100, 153)
19/19 143 (97, 189) 143 (98, 187) 146 (124, 167) 117 (90, 144)
aThe associated 95% confidence limits are given in parentheses.
bAdjusted for age.
Table 4 Characteristics of subjects
a included in the IGF1 genotype/breast cancer risk analysis by racial/ethnic group
African American Japanese American Non-Latino White Latino-American P-homo
b
Variable (cases/controls) (cases/controls) (cases/controls) (cases/controls) (cases/controls)
No. of subjects 81/91 76/94 82/92 81/96
Mean age (years) 68.1/67.9 68.5/68.4 68.9/67.6 68.4/67.0 0.85/0.47
P (t-test)
c 0.88 0.85 0.15 0.13
Mean height (in) 64.4/64.4 60.9/60.6 64.0/63.7 61.8/62.2 o0.0001/o0.0001
P (t-test)
c 0.82 0.47 0.48 0.19
Mean weight (lbs) 171.9/166.9 125.6/122.3 150.9/147.4 150.0/151.9 o0.0001/o0.0001
P (t-test)
c 0.36 0.30 0.45 0.69
Mean BMI (kg m
 2) 29.2/28.3 23.8/23.4 26.0/25.6 27.7/27.6 o0.0001/o0.0001
P (t-test)
c 0.30 0.41 0.58 0.85
aOf the 373 controls selected for this case–control data set, 134 overlapped with controls selected for the plasma IGF1 by racial/ethnic group analysis (Tables 1–3).
bP-value for homogeneity across all four racial/ethnic groups: cases/controls.
cP-value for difference between means between cases vs controls.
Table 5 Risk of breast cancer associated with IGF1 (CA)n microsatellite genotype by racial/ethnic group
a
Race Genotype CA (%) CO (%) OR 95%CL
b OR 95%CL
c P-trend
African American Non-19/non-19 24 (30) 39 (43) 1.00 1.00
Non-19/19 46 (57) 39 (43) 1.92 (0.99, 3.72) 1.99 (1.00, 3.96)
19/19 11 (14) 13 (14) 1.38 (0.53, 3.56) 1.32 (0.50, 3.47) 0.25
Japanese American Non-19/non-19 27 (36) 32 (34) 1.00 1.00
Non-19/19 35 (46) 51 (54) 0.81 (0.42, 1.59) 0.81 (0.41, 1.63)
19/19 14 (18) 11 (12) 1.51 (0.59, 3.87) 1.46 (0.56, 3.82) 0.65
Non-Latino White Non-19/non-19 12 (15) 8 (9) 1.00 1.00
Non-19/19 26 (32) 47 (51) 0.37 (0.13, 1.02) 0.35 (0.13, 0.99)
19/19 44 (54) 37 (40) 0.79 (0.29, 2.15) 0.82 (0.30, 2.24) 0.59
Latino American Non-19/non-19 7 (9) 16 (17) 1.00 1.00
Non-19/19 46 (57) 43 (45) 2.44 (0.92, 6.52) 2.27 (0.84, 6.16)
19/19 28 (35) 37 (39) 1.73 (0.63, 4.77) 1.76 (0.62, 4.97) 0.40
All races combined Non-19/non-19 70 (22) 95 (26) 1.00 1.00
Non-19/19 153 (48) 180 (48) 1.15 (0.79, 1.68) 1.14 (0.78, 1.68)
d
19/19 97 (30) 98 (26) 1.34 (0.89, 2.04) 1.40 (0.90, 2.20)
d 0.13
d
aOf the 373 controls selected for this case–control data set, 134 overlapped with controls selected for the plasma IGF1 by racial/ethnic group analysis (Tables 1–3).
bCrude.
cAdjusted for age as a categorical variable.
dAdditionally adjusted for race.
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Table 4 shows characteristics of the 693 subjects in the case–
control analysis of the IGF1 (CA)19 microsatellite and breast cancer
risk. Ages of participants at blood draw ranged from 49 through 81
years. Mean age at blood draw did not differ significantly across
racial/ethnic groups or between cases and controls in each racial/
ethnic stratum. The pattern of body size characteristics (height,
weight and BMI) in these 693 women is similar to those described
for the 230 control participants in the mean IGF1 plasma analysis
described above. As shown in Table 4, African-American women
had the highest BMI scores (29.2 for cases and 28.3 for controls),
Non-Latino White and Latino-Americans were intermediate and
Japanese Americans had the lowest BMI scores (23.8 for cases and
23.4 for controls). Although body size differed significantly across
racial/ethnic groups, differences were not significantly different
between cases and controls.
The distribution of genotypes for the (CA)n dinucleotide repeat
among controls in the case–control analysis (data not shown) is
similar to the distribution shown for the controls in the plasma
IGF1 analysis shown in Table 1. Of the controls in the case–control
analysis, 134 were included as controls in the analysis of plasma
IGF1 levels by racial/ethnic group. The distribution of genotypes
by case–control status is presented in Table 5. Results are
presented for all stages of breast cancer combined (excluding
ductal carcinoma in situ, (DCIS); N¼320). Stratification by stage
of disease (localised or regional and metastatic disease combined)
did not significantly alter the results from those presented here.
The 19/19 genotype was not predictive of low breast cancer risk in
our sample of postmenopausal African-American, Japanese-
American or Latino-American women. In Non-Latino Whites,
the adjusted odds ratio for breast cancer risk associated with
the 19/19 homozygote as compared to the baseline non-19/non-19
genotype was 0.82, but this protective effect was not stati-
stically significant (95% CI 0.30–2.24) (Table 5). When all
races are combined, the 19 allele seemed to be associated
with an increased risk for breast cancer. When dichotomised
into non-19 vs any-19 categories the risk effect was 1.21 (95% CI
0.83–1.75).
DISCUSSION
We found that circulating IGF1 levels in postmenopausal women
differed significantly between Latino-American women and three
other racial/ethnic groups. In our sample, Latino-American
women had low IGF1 levels. African-American, Japanese-American
and Non-Latino White women had higher circulating IGF1 levels
relative to the Latino-American women. When analysing recent
breast cancer rates calculated for the MEC, Pike et al found the
highest rates of breast cancer among African-Americans followed
by Japanese-Americans, Non-Latino Whites and Latino-Americans
(Pike et al, 2002). The observed relative rates (compared to
Whites) of Japanese-American, US-born Latinos, African Amer-
icans and Non-US-born Latinos are 1.00, 0.86, 0.83, 0.77,
respectively. These relative rates were adjusted for seven breast
cancer risk factors including age at and type of menopause,
age at menarche, age at first birth, number of children, weight,
HRT use and physical activity (Pike et al, 2002). In our MEC
sample plasma IGF1 levels were thus high among the three racial/
ethnic groups with high breast cancer rates and lowest among
the racial/ethnic group with the lowest breast cancer rates.
In accordance with the suggestion from previous epidemio-
logical (Bohlke et al, 1998; Hankinson et al, 1998; Byrne et al,
2000) and experimental (Furlanetto and DiCarlo, 1984;
Westley and May, 1994; Kleinberg, 1998) studies, our results
support further investigation of the role of IGF1 in breast cancer
aetiology.
We were unable to identify the IGF1 (CA)19 genotype as a
relevant genetic marker for cumulative lifetime exposure of breast
cells to IGF1. In our study population of postmenopausal women
from four different racial/ethnic backgrounds, the IGF1 (CA)19
genotype was not consistently correlated with circulating IGF1
levels and thus explained neither the interindividual nor the inter-
racial variation in blood IGF1 concentrations. Our result was
consistent with the absence of an association in a recent study of
Caucasian men (Allen et al, 2002), but contradicted the finding by
Rosen et al (1998) on the association between the (CA)19
dinucleotide repeat in the IGF1 gene and low serum IGF1 levels
in Caucasian men and postmenopausal women. Our results
suggested that the previous finding by Rosen et al may have been
a chance finding given that the categorisation of microsatellite
alleles was not based on functional evidence. Alternatively, the
genotype/phenotype correlation observed by Rosen et al may have
been specific for their study population because of a nearby
functional genetic variant in linkage disequilibrium with the
microsatellite repeat.
In this study, we stratified analyses by racial/ethnic group. After
stratification by race and genotype, the numbers in some strata
became quite small, a fact that detracted from statistical power.
There was some potential for random misclassification in genotype
determination that may have biased our outcome towards null.
Our careful control and checking process was designed to
minimise the probability of this occurrence (see Materials and
Methods). Some confidence has been gained by the fact that
the distribution of allele frequencies was consistent with Hardy–
Weinberg.
Future work in this area should involve analysis of larger
multiethnic samples, exploration for relevant determinants and
markers of IGF1 levels in the blood, in order to resolve the issue of
causal involvement of IGF1 in the aetiology of postmenopausal
breast cancer.
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